In the statement made by Pfizer/BioNTech, it was stated that in the phase 2 and 3 studies of the vaccine, an immune response (antibody level) matching what they had previously observed in the 16-25 age group in children aged 5-11 years.
Pfizer President Albert Bourla, whose views are included in the statement, stated that the cases of COVID-19 in children have increased by approximately 240 percent since July in the USA, “emphasizing the need for public health vaccination. Clinical trial results provide a strong basis for the approval of our vaccine for children aged 5 to 11 We plan to immediately submit the results to the FDA and other authorities.” used the phrases.
BioNTech CEO and Co-Founder Prof. Dr. Uğur Şahin also stated that they are happy to submit data for school-age children to the authorities before the winter season starts.
BioNTech’s co-founder Dr. Özlem Türeci stated on September 10 that they are preparing the production of the COVID-19 vaccine for children under the age of 12; announced that the vaccine would be the same but in lesser doses.